Sunday, November 16, 2025 11/16/2025

Genome-wide methylation and proteomic analysis of uterine lavage and cervical swab for early detection of ovarian cancer

Award Number: U2CCA271871
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: COOPERATIVE AGREEMENT
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 09/01/2022
PERIOD OF PERFORMANCE END DATE: 08/31/2028

Group Awards By:

View Award Description

Genome-wide methylation and proteomic analysis of uterine lavage and cervical swab for early detection of ovarian cancer - Project Summary/Abstract – Overall A three-decade research program developing, optimizing, and testing an annual blood-based test for the early detection of ovarian cancer in normal risk postmenopausal women failed to show a cancer-specific mortality reduction. The likely fundamental reason for the failure is the short window of opportunity provided by a blood-based signal. The proposed BCC will seek to identify an alternative biospecimen for the source of signal which has a much greater window of time for detection in early-stage disease so that an annual testing frequency will have a high likelihood of detecting ovarian cancer during its curable stages. Due to the direct connection of the uterus to the fallopian tube, where the cell of origin resides, a uterine lavage will likely contain the earliest biological signals of the presence of ovarian cancer. Identifying a minimal ovarian cancer signal amongst a much greater background of uterine epithelium cells and cellular material requires a very sensitive test. Our BCC will build on a recently developed innovative genome-wide methylation test and combine it with a sensitive antibody based proteomic test. Having optimized the combined test to detect a signal in uterine lavage, the BCC will determine its sensitivity in Pap smears. The BCC will optimize the combined test on training uterine lavage samples, validate the test on independent validation cohort of uterine lavage samples, and assess its performance in Pap smear samples. If the optimized test is sensitive in Pap smears, then the overall goal of a clinically acceptable and readily performed test (Pap smear) conducted at a feasible frequency of every 12 months will be a crucial step towards an annual test for the early detection of ovarian cancer in normal risk postmenopausal women, the population in which 80% of ovarian cancers occur. The long-term goal is an early detection program resulting in a significant reduction in ovarian cancer mortality. The intended use of the test developed by the BCC will be as a clinical decision-support tool for screening normal risk postmenopausal women for early detection of ovarian cancer. Such a test will fill an unmet health gap since there is currently no early detection test for ovarian cancer.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2025 ( Subtotal = $952,713 )
2025	2025	THE GENERAL HOSPITAL CORPORATION	55 FRUIT ST	BOSTON	MA	02114	SUFFOLK	USA	Cancer Detection and Diagnosis Research	001	3	9/11/2025	NON-COMPETING CONTINUATION	$952,713
2025	2023	THE GENERAL HOSPITAL CORPORATION	55 FRUIT ST	BOSTON	MA	02114	SUFFOLK	USA	Cancer Detection and Diagnosis Research	000	2	3/19/2025	NON-COMPETING CONTINUATION	$0
														Subtotal = $952,713

Issue Date FY: 2024 ( Subtotal = $0 )
2024	2023	THE GENERAL HOSPITAL CORPORATION	55 FRUIT ST	BOSTON	MA	02114	SUFFOLK	USA	Cancer Detection and Diagnosis Research	000	2	7/23/2024	NON-COMPETING CONTINUATION	$0
														Subtotal = $0

Issue Date FY: 2023 ( Subtotal = $922,892 )
2023	2023	THE GENERAL HOSPITAL CORPORATION	55 FRUIT ST	BOSTON	MA	02114	SUFFOLK	USA	Cancer Detection and Diagnosis Research	000	2	8/30/2023	NON-COMPETING CONTINUATION	$922,892
														Subtotal = $922,892

Issue Date FY: 2022 ( Subtotal = $686,372 )
2022	2022	MASSACHUSETTS GENERAL HOSPITAL, THE	55 FRUIT ST	BOSTON	MA	02114	SUFFOLK	USA	Cancer Detection and Diagnosis Research	000	1	8/1/2022	NEW	$686,372
														Subtotal = $686,372

Grand Total All Awards = $2,561,977

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Genome-wide methylation and proteomic analysis of uterine lavage and cervical swab for early detection of ovarian cancer

Award Number: U2CCA271871

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: COOPERATIVE AGREEMENT

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 09/01/2022

PERIOD OF PERFORMANCE END DATE: 08/31/2028

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer